Parkwalk Advisors and Cambridge Innovation Capital have backed the pet antibody therapeutics developer, a spinout of Wellcome Sanger Institute.

PetMedix, a UK-based pet-focused antibody treatment developer, closed a £27m ($37m) series B round yesterday that included patient capital fund Cambridge Innovation Capital (CIC) and Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group.
Pharmaceutical and veterinary group Kyoritsu Holding and internet company Tencent also took part in the round, as did venture capital firm Digitalis Ventures.
Spun out of University of Cambridge-affiliated genetics research organisation Wellcome Sanger Institute in 2018, PetMedix is developing veterinary antibody…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in